Co-Inventors
Lusso, Paolo
Zhang, Peng
Ciaramella, Giuseppe
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
This innovative HIV immunization strategy relies on mRNA technology to prime and boost immune responses, using full-length or minimally truncated Env proteins to maintain native conformation for effective membrane expression. Co-formulating Env and Gag proteins promotes virus-like particle (VLP) production in vivo, mimicking HIV's structure for better immune recognition. The regimen involves an intensive schedule of 8+ sequential immunizations and includes boosting with diverse Envs from different HIV-1 clades to broaden the immune response. By using only glycan-repaired, tier-2 Env immunogens, the strategy avoids vaccine-irrelevant epitopes and glycan holes that could elicit non-neutralizing antibodies, focusing the immune response on generating broadly neutralizing antibodies.
Commercial Applications
This mRNA-based immunization strategy has broad potential applications. Its adaptability allows for rapid development of vaccines against new pathogens, vital for pandemic response. The strategy's ability to induce potent immune responses and generate broadly neutralizing antibodies makes it promising for vaccines against challenging viruses like influenza. Additionally, its flexibility enables personalized cancer vaccines, harnessing the immune system against specific tumor antigens. This approach could revolutionize vaccine development and enhance our ability to prevent and treat various diseases.
Competitive Advantages
This mRNA-based HIV immunization strategy offers unique advantages. Its adaptability to new viral strains is unmatched, crucial for combating HIV's genetic diversity. By maintaining native protein conformation, it enhances immune recognition, and co-formulating Env and Gag promotes potent immune responses. The intensive schedule and diverse boosting aim to elicit broadly neutralizing antibodies, a key challenge in HIV vaccine development. Additionally, its focus on glycan-repaired Env minimizes the risk of non-neutralizing antibody responses, potentially enhancing vaccine efficacy.
